Theravance Biopharma Inc (TBPH) Expected to Announce Earnings of -$1.18 Per Share

Share on StockTwits

Wall Street brokerages expect Theravance Biopharma Inc (NASDAQ:TBPH) to post earnings per share of ($1.18) for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Theravance Biopharma’s earnings, with the lowest EPS estimate coming in at ($1.26) and the highest estimate coming in at ($1.02). Theravance Biopharma posted earnings per share of ($1.27) in the same quarter last year, which would suggest a positive year over year growth rate of 7.1%. The company is scheduled to report its next quarterly earnings report on Tuesday, November 6th.

According to Zacks, analysts expect that Theravance Biopharma will report full year earnings of ($4.41) per share for the current financial year, with EPS estimates ranging from ($4.70) to ($4.22). For the next year, analysts anticipate that the firm will report earnings of ($4.29) per share, with EPS estimates ranging from ($5.09) to ($3.72). Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for Theravance Biopharma.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Wednesday, August 1st. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.20) by $0.44. Theravance Biopharma had a negative return on equity of 261.70% and a negative net margin of 640.07%. The company had revenue of $23.48 million during the quarter, compared to the consensus estimate of $9.97 million.

TBPH has been the subject of several analyst reports. BidaskClub raised Theravance Biopharma from a “sell” rating to a “hold” rating in a research report on Friday, July 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $40.00 target price on shares of Theravance Biopharma in a research report on Wednesday, August 1st. Cantor Fitzgerald set a $55.00 target price on Theravance Biopharma and gave the stock a “buy” rating in a research report on Wednesday, August 1st. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $55.00 target price on shares of Theravance Biopharma in a research report on Wednesday, August 1st. Finally, ValuEngine raised Theravance Biopharma from a “hold” rating to a “buy” rating in a research report on Thursday, August 9th. Two investment analysts have rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $40.60.

Shares of NASDAQ TBPH traded up $0.10 on Friday, hitting $29.94. The company had a trading volume of 146,318 shares, compared to its average volume of 235,388. Theravance Biopharma has a 12-month low of $21.27 and a 12-month high of $35.48. The company has a debt-to-equity ratio of 6.52, a current ratio of 4.14 and a quick ratio of 3.95. The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of -5.49 and a beta of 1.88.

In related news, SVP Philip D. Worboys sold 6,393 shares of the stock in a transaction dated Wednesday, September 12th. The stock was sold at an average price of $28.50, for a total value of $182,200.50. Following the completion of the transaction, the senior vice president now owns 166,753 shares of the company’s stock, valued at $4,752,460.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Bradford J. Shafer sold 31,300 shares of the stock in a transaction dated Wednesday, August 8th. The shares were sold at an average price of $27.94, for a total value of $874,522.00. Following the completion of the transaction, the executive vice president now directly owns 127,606 shares of the company’s stock, valued at approximately $3,565,311.64. The disclosure for this sale can be found here. Insiders sold 88,555 shares of company stock valued at $2,425,865 in the last three months. 6.90% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Rhumbline Advisers boosted its holdings in Theravance Biopharma by 4.6% in the second quarter. Rhumbline Advisers now owns 39,781 shares of the biopharmaceutical company’s stock valued at $902,000 after purchasing an additional 1,757 shares during the last quarter. UBS Group AG boosted its holdings in Theravance Biopharma by 88.4% in the first quarter. UBS Group AG now owns 4,511 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 2,117 shares during the last quarter. Royal Bank of Canada boosted its holdings in Theravance Biopharma by 22.3% in the first quarter. Royal Bank of Canada now owns 16,664 shares of the biopharmaceutical company’s stock valued at $404,000 after purchasing an additional 3,042 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its holdings in Theravance Biopharma by 12.2% in the second quarter. State Board of Administration of Florida Retirement System now owns 28,578 shares of the biopharmaceutical company’s stock valued at $648,000 after purchasing an additional 3,100 shares during the last quarter. Finally, Swiss National Bank boosted its holdings in Theravance Biopharma by 5.3% in the first quarter. Swiss National Bank now owns 75,142 shares of the biopharmaceutical company’s stock valued at $1,822,000 after purchasing an additional 3,800 shares during the last quarter. 85.80% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.

See Also: What is Compound Annual Growth Rate (CAGR)?

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.